蒙牛(02319.HK)中績多賺1.4倍 股價逆市續漲7%
亞太區主要股市今早普遍逆美股受壓,其中滬指及深成跌0.5%及0.9%,報3,521及14,558。恆指現報25,600,續吐93點,成交額406億元。
不過,蒙牛乳業(02319.HK)中績多賺1.4倍,該股承過去三連升勢,今早進一步升破百天線及50天線(44.5元),最高見47元,現報46.9元,續升7%,為最強藍籌,成交增至884萬股。
蒙牛公布,中期純利按年增長1.4倍至29.47億元人民幣(下同),每股盈利74.8分,維持不派中期息。期內,收入按年增長22%至459.05億元;整體毛利率按年微降0.8個百分點至38.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.